Research programme: chemokine therapeutics - Biokine Therapeutics

Alternative Names: BKT 130; BKT-RP3

Latest Information Update: 20 Sep 2017

Price : $50 ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Biokine Therapeutics
Class Antibodies
Mechanism of Action Chemokine modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer
Discontinued Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

20 Sep 2017 Discontinued - Preclinical for Multiple sclerosis in Israel (IV)
20 Sep 2017 Discontinued - Preclinical for Rheumatoid arthritis in Israel (IV)
20 Sep 2017 Preclinical trials in Cancer in Israel (unspecified route) (Biokine Therapeutics pipeline, September 2017)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight